Largest pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 52 pharmaceutical companies ranked by revenue, at NOK 913.6B, ahead of Eli Lilly (NOK 632.2B) and Merck & Co (NOK 630.5B). Figures as of 19 Nov 2026, 00:16 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- First
- Johnson & JohnsonNOK 913.6B
- Median
- NOK 31.1B
- Combined market value
- NOK 49.07T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | NOK 913.6B | NOK 6.37T | NOK 2,644.93 | 2.15% down | 38% up | ||
| 2 | Eli LillyLLY · Health Care | NOK 632.2B | NOK 11.95T | NOK 13,411.36 | 2.32% down | 35% up | ||
| 3 | Merck & CoMRK · Health Care | NOK 630.5B | NOK 3.29T | NOK 1,336.34 | 3.90% down | 51% up | ||
| 4 | PfizerPFE · Health Care | NOK 607B | NOK 1.55T | NOK 272.16 | 1.44% down | 14% up | ||
| 5 | AbbVieABBV · Health Care | NOK 593.2B | NOK 4.9T | NOK 2,774.03 | 2.33% down | 26% up | ||
| 6 | AstraZenecaAZN · Health Care | NOK 569.7B | NOK 2.69T | NOK 1,733.80 | 1.93% down | 2% up | ||
| 7 | NovartisNVS · Health Care | NOK 528.9B | NOK 2.84T | NOK 1,505.39 | 2.46% down | 25% up | ||
| 8 | SanofiSNY · Health Care | NOK 469.5B | NOK 1.1T | NOK 457.02 | 0.86% down | 4% down | ||
| 9 | Bristol-Myers SquibbBMY · Health Care | NOK 467.4B | NOK 1.18T | NOK 577.68 | 2.92% down | 34% up | ||
| 10 | Novo NordiskNVO · Health Care | NOK 444.8B | NOK 1.69T | NOK 382.43 | 3.12% down | 17% down | ||
| 11 | Abbott LaboratoriesABT · Health Care | NOK 429.9B | NOK 1.76T | NOK 1,013.36 | 0.22% down | 17% down | ||
| 12 | GSKGSK · Health Care | NOK 420.6B | NOK 944.5B | NOK 471.18 | 1.34% down | 6% up | ||
| 13 | Takeda PharmaceuticalTAK · Health Care | NOK 273.7B | NOK 659.1B | NOK 206.30 | 1.71% down | 54% up | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | NOK 167.4B | NOK 477.9B | NOK 409.59 | 0.92% down | 74% up | ||
| 15 | Regeneron PharmaceuticalsREGN · Health Care | NOK 139.1B | NOK 948.7B | NOK 9,170.74 | 1.28% down | 36% up | ||
| 16 | ViatrisVTRS · Health Care | NOK 138.7B | NOK 225.5B | NOK 196.70 | 0.83% down | 96% up | ||
| 17 | Vertex PharmaceuticalsVRTX · Health Care | NOK 116.4B | NOK 1.32T | NOK 5,203.06 | 0.42% up | 27% up | ||
| 18 | ZoetisZTS · Health Care | NOK 91.8B | NOK 337.2B | NOK 829.95 | 2.50% up | 29% down | ||
| 19 | GrifolsGRFS · Health Care | NOK 81B | NOK 55.9B | NOK 82.15 | 1.85% down | 1% up | ||
| 20 | BeOne MedicinesONC · Health Care | NOK 51.8B | NOK 447.1B | NOK 3,914.54 | 2.34% down | 17% up | ||
| 21 | Elanco Animal HealthELAN · Health Care | NOK 45.7B | NOK 129.4B | NOK 258.96 | 3.29% up | 20% up | ||
| 22 | Jazz PharmaceuticalsJAZZ · Health Care | NOK 41.4B | NOK 154.3B | NOK 2,403.13 | 2.93% up | 37% up | ||
| 23 | GenmabGMAB · Health Care | NOK 36.1B | NOK 304.8B | NOK 494.36 | 1.91% down | 70% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | NOK 36B | NOK 194.1B | NOK 1,449.04 | 4.54% down | 66% down | ||
| 25 | Dr. Reddy's LaboratoriesRDY · Health Care | NOK 34.7B | NOK 121.1B | NOK 145.29 | 1.28% up | 5% up | ||
| 26 | BioMarin PharmaceuticalBMRN · Health Care | NOK 31.2B | NOK 115.4B | NOK 595.81 | 4.99% up | 11% up | ||
| 27 | United TherapeuticsUTHR · Health Care | NOK 30.9B | NOK 238.5B | NOK 5,599.65 | 1.16% down | 23% up | ||
| 28 | Amneal PharmaceuticalsAMRX · Health Care | NOK 29.3B | NOK 73.9B | NOK 212.22 | 3.60% up | 83% up | ||
| 29 | Royalty PharmaRPRX · Health Care | NOK 23.1B | NOK 383B | NOK 666.03 | 0.01% down | 78% up | ||
| 30 | PTC TherapeuticsPTCT · Health Care | NOK 16.8B | NOK 48.8B | NOK 584.17 | 0.22% down | 20% down | ||
| 31 | AlkermesALKS · Health Care | NOK 14.3B | NOK 76.4B | NOK 454.40 | 3.08% up | 58% up | ||
| 32 | Legend BiotechLEGN · Health Care | NOK 10B | NOK 30.6B | NOK 157.61 | 0.87% up | 42% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | NOK 9.3B | NOK 89.7B | NOK 3,861.00 | 5.67% down | 24% down | ||
| 34 | Ionis PharmaceuticalsIONS · Health Care | NOK 9.2B | NOK 44.2B | NOK 265.66 | 1.59% up | 64% down | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | NOK 8B | NOK 59.1B | NOK 418.13 | 0.28% up | 10% up | ||
| 36 | Ascendis PharmaASND · Health Care | NOK 7.7B | NOK 172B | NOK 2,621.94 | 0.32% down | 28% up | ||
| 37 | Corcept TherapeuticsCORT · Health Care | NOK 7.4B | NOK 72B | NOK 657.50 | 3.25% down | 8% down | ||
| 38 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | NOK 6.6B | NOK 72.4B | NOK 921.89 | 0.06% down | 126% up | ||
| 39 | Axsome TherapeuticsAXSM · Health Care | NOK 6.2B | NOK 68.4B | NOK 1,299.67 | 1.43% down | 7% down | ||
| 40 | TG TherapeuticsTGTX · Health Care | NOK 6B | NOK 96.9B | NOK 641.30 | 5.44% up | 107% up | ||
| 41 | InsmedINSM · Health Care | NOK 5.9B | NOK 254.9B | NOK 1,161.95 | 1.69% down | 40% down | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | NOK 5.1B | NOK 58.6B | NOK 897.07 | 0.59% up | 31% up | ||
| 43 | BridgeBio PharmaBBIO · Health Care | NOK 4.9B | NOK 147.4B | NOK 756.62 | 1.58% up | 17% up | ||
| 44 | Travere TherapeuticsTVTX · Health Care | NOK 4.8B | NOK 46.8B | NOK 487.28 | 1.68% down | 44% up | ||
| 45 | Ligand PharmaceuticalsLGND · Health Care | NOK 2.6B | NOK 58B | NOK 2,897.20 | 1.67% up | 43% up | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | NOK 1.8B | NOK 80B | NOK 1,154.57 | 2.08% up | 13% up | ||
| 47 | CytokineticsCYTK · Health Care | NOK 853.9M | NOK 69.3B | NOK 497.76 | 0.64% down | 20% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | NOK 446.3M | NOK 80.5B | NOK 1,233.33 | 2.00% up | 46% up | ||
| 49 | Roivant SciencesROIV · Health Care | NOK 80.1M | NOK 272.2B | NOK 375.64 | 0.05% up | 90% up | ||
| 50 | Dianthus TherapeuticsDNTH · Health Care | NOK 19.7M | NOK 45.9B | NOK 814.53 | 3.45% down | 113% up | ||
| 51 | Spyre TherapeuticsSYRE · Health Care | NOK 0 | NOK 93.5B | NOK 984.07 | 8.15% up | 286% up | ||
| 52 | Praxis Precision MedicinesPRAX · Health Care | NOK 0 | NOK 82.7B | NOK 2,960.05 | 0.04% up | 61% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6990 NOK). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by revenue?
Johnson & Johnson (NOK 913.6B), Eli Lilly (NOK 632.2B) and Merck & Co (NOK 630.5B) are the top three of the 52 pharmaceutical companies ranked by revenue as of 19 Nov 2026, 00:16 UTC.
How many pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 52 pharmaceutical companies ranked by revenue have a combined market value of NOK 49.07T as of 19 Nov 2026, 00:16 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies by revenue”, data as of 19 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.